You are here

Francisca Vazquez


Chan E, et al. WRN Helicase is a Synthetic Lethal Target in Microsatellite Unstable Cancers. Nature. April 10, 2019.

Price C, et al.Genome-wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Research. March 21, 2019.

Howard TP, et al.MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Research. February 12, 2019.

McFarland JM, et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nature Communications. 9:4610 (2018)

Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a Cancer Dependency Map. Cell. 2017;170(3):564-576.e16.

Francisca Vazquez, Ph.D.

Francisca Vazquez is the associate director of the Cancer Dependency Map Project (DepMap) at the Broad Institute, a programmatic effort that she co-leads to systematically identify all cancer dependencies in human cancer.

The DepMap project is an effort to comprehensively identify genetic dependencies and small molecules sensitivities and the molecular markers that predict their response across thousands of cancer cell line models to accelerate precision cancer medicine. To accomplish this goal, Vazquez works with a large interdisciplinary team of project managers, basic scientists, and computational biologists that uses state-of-the-art genome-scale functional genomics, including CRISPR and high-throughput small molecule screening technologies, to systematically profile hundreds of cellular models of cancers.

Vazquez also leads DepMap’s target discovery and advancement team, which focuses on developing methods to systematically identify the most promising therapeutic targets and translate the findings to therapeutics. Vazquez launched the Pediatric Dependency Map and the GI Dependency Map projects, which she co-leads with faculty members, to create a comprehensive catalog of vulnerabilities in those tumor types. Her main goal is to help accelerate precision cancer medicine by both creating resources for the scientific community, such as DepMap, and identifying and validating the most promising targets and biomarkers.

Prior to joining the Broad Institute in 2011, Vazquez worked as a research scientist at Dana-Farber Cancer Institute in the center for chronic disease, studying cancer metabolism; her postdoctoral work, which focused on tumor suppressor genes, was also undertaken at DFCI. She earned her Ph.D. from the University of Illes Balears in Spain, while performing most of her work as a visiting student at Beth-Israel Deaconess Medical Center.

April 2019